Sort
30,917 grants matching “tumor microenvironment”
Chemotherapy-induced MDSCs and antitumor immunity
$337,268Gang Zhou · Augusta University · R01 · FY2019 · CA
Clinical Trials Program
$337,247Margaret M Madeleine · Fred Hutchinson Cancer Center · U54 · FY2024 · CA
Targeting Glioblastoma Cells and Tumor Microenvironment with CAR-T Cell Therapy
$337,209Yvonne Yu-Hsuan Chen · University Of California Los Angeles · P50 · FY2024 · CA
Core B: Liver Metastasis Resource Core (LMRC)
$337,190Edwin Melencio Posadas · Cedars-Sinai Medical Center · P01 · FY2023 · CA
Xenograft-like rejection of tumors in a-gal glycolipids
$337,188Uri Galili · Univ Of Massachusetts Med Sch Worcester · R01 · FY2010 · CA
Xenograft-like rejection of tumors in a-gal glycolipids
$337,188Uri Galili · Univ Of Massachusetts Med Sch Worcester · R01 · FY2009 · CA
Xenograft-like rejection of tumors in a-gal glycolipids
$337,188Uri Galili · Univ Of Massachusetts Med Sch Worcester · R01 · FY2008 · CA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain
$337,106Todd W Vanderah · University Of Arizona · R01 · FY2020 · CA
Cannabinoid CB2 Agonists for Treatment of Breast Cancer Induced Bone Pain
$337,106Todd W Vanderah · University Of Arizona · R01 · FY2021 · CA
Targeted Isolation and Identification of Sialylated Glycoproteins in Cancer Tissues, Cells and Biofluids
$337,036Richard R Drake · Medical University Of South Carolina · R33 · FY2022 · CA
Endothelial PHD2/HIF Axis in Ischemic Kidney Injury and Inflammation
$336,940Pinelopi P. Kapitsinou · Northwestern University At Chicago · R01 · FY2020 · DK
Molecular and Cellular Mechanisms of Tumor Development
$336,921Caroline Margaret Alexander · University Of Wisconsin-Madison · T32 · FY2012 · CA
Strategies to improve outcomes for TNBC patients that integrate subtype-specific genomic and immune-based discoveries
$336,917Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2023 · CA
Strategies to improve outcomes for TNBC patients that integrate subtype-specific genomic and immune-based discoveries
$336,917Jennifer A Pietenpol · Vanderbilt University Medical Center · P50 · FY2022 · CA
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC
$336,881William G Hawkins · Washington University · P50 · FY2023 · CA
OV therapy induced changes in tumor secretome and their impact on therapy
$336,875Balveen Kaur · Ohio State University · R01 · FY2015 · NS
OV therapy induced changes in tumor secretome and their impact on therapy
$336,875Balveen Kaur · University Of Texas Hlth Sci Ctr Houston · R01 · FY2017 · NS
OV therapy induced changes in tumor secretome and their impact on therapy
$336,875Balveen Kaur · Ohio State University · R01 · FY2016 · NS
Mechanisms that Regulate Thymic Involution and Age-Associated Changes in T-Cells
$336,847Dennis D. Taub · National Institute On Aging · ZIA · FY2010 · AG
The Molecular Profile of Prostate Tumors in African-American Men
$336,842Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
$336,835Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2024 · CA
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors
$336,830Roberto Pili · Roswell Park Cancer Institute Corp · R01 · FY2009 · CA
Targeted immunotherapy for relapsed/refractory Hodgkin lymphoma
$336,786Alex F. Herrera · Beckman Research Institute/City Of Hope · P50 · FY2018 · CA
Developing therapeutic strategies to elicit metabolic synthetic lethality in glioblastoma
$336,769Prakash Chinnaiyan · William Beaumont Hospital Research Inst · R01 · FY2021 · NS
Mechanisms of glioma growth and invasion novel therapeutic strategies
$336,755Pedro R Lowenstein · University Of Michigan At Ann Arbor · R01 · FY2014 · NS